Get the Stockscreener App
1.79
7.83%
0.13
After Hours:
1.77
-0.02
-1.12%
Theratechnologies Inc stock is traded at $1.79, with a volume of 372.33K.
It is up +7.83% in the last 24 hours and up +46.72% over the past month.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
See More
Previous Close:
$1.66
Open:
$1.68
24h Volume:
372.33K
Relative Volume:
5.72
Market Cap:
$82.30M
Revenue:
$84.32M
Net Income/Loss:
$-3.16M
P/E Ratio:
-1.4672
EPS:
-1.22
Net Cash Flow:
$-4.50M
1W Performance:
+17.76%
1M Performance:
+46.72%
6M Performance:
+42.06%
1Y Performance:
+18.54%
1-Day Range:
$1.5302
$1.80
1-Week Range:
$1.52
$1.8499
52-Week Range:
$1.08
$2.58
Theratechnologies Inc Stock (THTX) Company Profile
Compare THTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THTX
Theratechnologies Inc
|
1.79 | 82.30M | 84.32M | -3.16M | -4.50M | -0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theratechnologies Inc Stock (THTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Theratechnologies Inc Stock (THTX) Latest News
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV® - TipRanks
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment - The Manila Times
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® ... - Russellville Courier
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Manufacturing Changes Amid Supply Concerns - StockTitan
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Closing Bell: Theratechnologies Up On Wednesday (TH) - Barchart
Theratechnologies (TSE:TH) Stock Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Decreases By 44.0% - MarketBeat
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - Marketscreener.com
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - GlobeNewswire
Theratechnologies Awaits FDA Decision on New EGRIFTA Formulation, Sets March 2025 PDUFA Date - StockTitan
Theratechnologies Shows Promise in Ovarian Cancer Trial - TipRanks
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer - GlobeNewswire
Theratechnologies' Cancer Drug Shows Promise: Tumor Shrinkage in Phase 1b Trial - StockTitan
Theratechnologies expands rare disease portfolio with Ionis partnership - MSN
Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance
Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing
Theratechnologies Expands Portfolio with Ionis Deal - TipRanks
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen - The Bakersfield Californian
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada - GlobeNewswire
Theratechnologies Secures Exclusive Rights to Two Breakthrough Rare Disease Drugs in $22.75M Deal - StockTitan
EGRIFTA SV production restarts after FDA inspection - Investing.com India
Theratechnologies resumes production of EGRIFTA SV - MSN
EGRIFTA SV production restarts after FDA inspection By Investing.com - Investing.com Nigeria
Theratechnologies resumes production of Egrifta SV - Nasdaq
Theratechnologies Announces Resumed Production of EGRIFTA SV® - GlobeNewswire
Theratechnologies Inc. Announces Resume Production of EGRIFTA SV - Marketscreener.com
Theratechnologies secures up to $75M in new credit facilities - Yahoo Finance
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec - GlobeNewswire
Theratechnologies Secures $75M Credit Facility with Improved Terms, Freeing Up $19M Cash - StockTitan
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and ... - Russellville Courier
Theratechnologies resubmits BLA for new tesamorelin formulation - MSN
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review - Marketscreener.com
Theratechnologies Resubmits Tesamorelin Application to FDA - TipRanks
Theratechnologies Resubmits FDA Application for Improved HIV Treatment Formulation | THTX Stock News - StockTitan
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability - Yahoo Finance
Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World
Theratechnologies Inc. (NASDAQ:THTX) Sees Large Growth in Short Interest - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 26.8% in October - Defense World
Theratechnologies (TSE:TH) Share Price Passes Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Lipodystrophy Market: Company Profiles, Segment Size, - openPR
Net Present Value Model: Theratechnologies Inc’s Sudocetaxel Zendusortide - GlobalData
Theratechnologies (TSE:TH) Stock Passes Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 226.0% - MarketBeat
Closing Bell: Theratechnologies Down On Monday (TH) - Barchart
THTX upgraded at Research Capital - Cantech Letter
Theratechnologies (TSE:TH) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV - The Manila Times
Theratechnologies reports use of HIV drug in severe cases - Investing.com
Theratechnologies reports use of HIV drug in severe cases By Investing.com - Investing.com South Africa
Theratechnologies Inc Stock (THTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):